The clinical utility of the myPath® Melanoma score has been evaluated in two separate studies to best represent multiple aspects of the diagnostic and treatment paradigms.

These studies with experienced dermatopathologists demonstrate that use of the test increases the number of definitive diagnoses,  decreases classification of lesions as ‘indeterminate’, and produces substantial changes in patient treatment.

Utility Study 1:

  • Prospective cohort (n=218) of cases submitted for testing in the clinical setting
  • 56.6% increase in definitive diagnoses in ambiguous cases8

Pre-Test Diagnosis

Hover over pie chart to view values

Pre-Test Diagnosis

Hover over pie chart to view values

  • Benign
  • Malignant
  • Indeterminate

Utility Study 2:

  • Prospective cohort (n=77) of ambiguous cases (“indeterminate” per dermatopathologist)
  • Compared referring dermatopathologist pre-test management recommendation with actual patient treatment received by patient post-test at 6-12 months follow-up
  • 71.4% change from pre-test treatment recommendation to actual treatment performed28

Pre-Test Diagnosis

Pre-Test Diagnosis

  • No Re-Excision
  • Re-Excision
  • LFU